IS8669A - Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í - Google Patents

Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Info

Publication number: IS8669A
Authority: IS; Iceland
Prior art keywords: homogeneity; ingredients; improved; rasagiline formulations; rasagiline
Prior art date: 2005-02-23

Application number

IS8669A

Other languages

English (en)

Inventor

Berger Peskin Tirtza

Original Assignee

Teva Pharmaceutical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-23

Filing date

2007-08-15

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-15 Application filed by Teva Pharmaceutical Industries, Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.

2007-08-15 Publication of IS8669A publication Critical patent/IS8669A/is

Links

238000009472 formulation Methods 0.000 title 1
239000004615 ingredient Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
229960000245 rasagiline Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IS8669A 2005-02-23 2007-08-15 Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í IS8669A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65562205P	2005-02-23	2005-02-23
US72090805P	2005-09-27	2005-09-27
PCT/US2006/006252 WO2006091657A1 (en)	2005-02-23	2006-02-22	Rasagiline formulations of improved content uniformity

Publications (1)

Publication Number	Publication Date
IS8669A true IS8669A (is)	2007-08-15

Family

ID=36927751

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8669A IS8669A (is)	2005-02-23	2007-08-15	Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Country Status (15)

Country	Link
US (1)	US7815942B2 (is)
EP (1)	EP1848402B2 (is)
JP (2)	JP5738509B2 (is)
KR (5)	KR20070111534A (is)
AU (1)	AU2006216696B2 (is)
BR (1)	BRPI0608209A2 (is)
CA (2)	CA2901244A1 (is)
ES (1)	ES2586412T5 (is)
IL (2)	IL184033A0 (is)
IS (1)	IS8669A (is)
MX (1)	MX2007010233A (is)
NO (1)	NO20074823L (is)
NZ (1)	NZ560660A (is)
RU (1)	RU2404746C2 (is)
WO (1)	WO2006091657A1 (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
DK1567152T3 (da)	2002-11-15	2013-10-07	Teva Pharma	Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
AU2005269416B2 (en) *	2004-07-26	2011-07-28	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) *	2004-11-24	2008-11-26	Teva Pharma	Rasagiline orally disintegrating compositions
EP1838326A4 (en) *	2005-02-02	2009-09-30	Teva Pharma	PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS
PT1848415E (pt) *	2005-02-17	2013-06-27	Teva Pharma	Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
JP5738509B2 (ja)	2005-02-23	2015-06-24	テバファーマシューティカルインダストリーズリミティド	内容物均一性が改善されたラサギリン製剤
CN101622225B (zh) *	2005-11-17	2015-04-15	泰华制药工业有限公司	炔丙基氨基茚分离方法
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
JP5701485B2 (ja)	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
WO2007117431A2 (en)	2006-04-03	2007-10-18	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) *	2006-12-14	2013-08-07	泰华制药工业有限公司	雷沙吉兰碱结晶固体
NZ577623A (en) *	2006-12-14	2011-05-27	Teva Pharma	Tannate salt of rasagiline
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) *	2007-09-05	2010-12-09	テバファーマシューティカルインダストリーズリミティド	ラサギリンを使用する緑内障の治療方法
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
MX2010007601A (es) *	2008-01-11	2010-08-03	Teva Pharma	Formulaciones de rasagilina, su preparacion y uso.
EP2271612B1 (en) *	2008-03-31	2016-08-10	Actavis Group PTC EHF	Rasagiline mesylate particles and process for the preparation thereof
JP2011524353A (ja) *	2008-06-10	2011-09-01	テバファーマシューティカルインダストリーズリミティド	ラサギリン軟ゼラチンカプセル
EA201170018A1 (ru) *	2008-06-13	2011-08-30	Тева Фармасьютикал Индастриз, Лтд.	Разагилин для изменения течения болезни паркинсона
CN102065853A (zh) *	2008-06-19	2011-05-18	泰华制药工业有限公司	制备和干燥固体雷沙吉兰碱的方法
EP2299993A4 (en)	2008-06-19	2014-08-20	Teva Pharma	PROCESS FOR PURIFYING THE BASE OF RASAGILINE
EP2358658A4 (en) *	2008-11-20	2012-11-14	Reddys Lab Ltd Dr	PREPARATION OF RASAGILIN AND ITS SALTS
DE102008064061A1 (de)	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) *	2009-01-23	2011-12-20	Teva Pharmaceuticals Industries, Ltd.	Delayed release rasagiline citrate formulation
WO2010100219A2 (en)	2009-03-05	2010-09-10	Sandoz Ag	Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
WO2010111264A2 (en) *	2009-03-24	2010-09-30	Dr. Reddy's Laboratories Ltd.	Rasagiline formulations
CA2767592A1 (en)	2009-07-09	2011-01-13	Ratiopharm Gmbh	Salts of rasagiline and pharmaceutical preparations thereof
US8741962B2 (en) *	2009-11-26	2014-06-03	Usv Limited	Process for preparation of Rasagiline and salts thereof
WO2011092717A2 (en) *	2010-02-01	2011-08-04	Alkem Laboratories Ltd.	Rasagiline mesylate having large particle size and a process for preparation thereof
RS55487B2 (sr) *	2010-02-12	2024-06-28	Pfizer	Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
CN108186611A (zh)	2010-04-30	2018-06-22	帝国制药美国公司	丙炔基氨基茚满透皮组合物
EP2389927A1 (en)	2010-05-30	2011-11-30	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Pharmaceutical formulations of rasagiline
RU2013108256A (ru)	2010-07-27	2014-09-10	Тева Фармасьютикал Индастриз Лтд.	Дисперсии цитрата разагилина
AU2011282720B2 (en)	2010-07-27	2016-12-22	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
WO2012129429A2 (en)	2011-03-24	2012-09-27	Teikoku Pharma Usa, Inc.	Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2012153349A2 (en)	2011-05-04	2012-11-15	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
AU2012323351A1 (en)	2011-10-10	2014-05-22	Teva Pharmaceutical Industries Ltd.	R(+)-N-methyl-propargyl-aminoindan
HK1200315A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	R(+)-n-formyl-propargyl-aminoindan
WO2013070526A1 (en)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Methods for the treatment of skin neoplasms
EP2610239A1 (en)	2012-01-02	2013-07-03	Dr. Reddy's Laboratories Ltd.	Preparation Of Rasagiline Hemitartrate
EP2827848B1 (en)	2012-03-21	2016-04-27	Synthon BV	Stabilized pharmaceutical compositions comprising rasagiline salts
JP2015529196A (ja)	2012-08-17	2015-10-05	テバファーマシューティカルインダストリーズリミティド	ラサギリンの非経口製剤
US9205061B2 (en)	2012-11-02	2015-12-08	Teikoku Pharma Usa, Inc.	Propynylaminoindan transdermal compositions
WO2014153145A2 (en)	2013-03-14	2014-09-25	Teva Pharmaceutical Industries Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
CA3062126C (en) *	2016-11-10	2021-04-27	Medisca Pharmaceutique Inc.	Container assembly and adapter therefor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3513249A (en) *	1968-12-24	1970-05-19	Ideal Ind	Explosion connector with improved insulating means
GB8914804D0 (en) *	1989-06-28	1989-08-16	Glaxo Group Ltd	Process
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5767164A (en) *	1991-04-04	1998-06-16	Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5444095A (en) *	1991-04-04	1995-08-22	University Of Toronto, Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL99759A (en)	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1995018617A1 (en)	1994-01-10	1995-07-13	Teva Pharmaceutical Industries Ltd.	1-aminoindan derivatives and compositions thereof
IL115357A (en) *	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PT966435E (pt)	1996-12-18	2005-06-30	Yissum Res Dev Co	Derivados aminoindano
CA2319318A1 (en) *	1998-01-27	1999-07-29	Thomas N. Thomas	Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl
US7766013B2 (en) *	2001-06-05	2010-08-03	Alexza Pharmaceuticals, Inc.	Aerosol generating method and device
PL370793A1 (en) *	2001-07-04	2005-05-30	Sun Pharmaceutical Industries Limited	Gastric retention controlled drug delivery system
US20040052843A1 (en) *	2001-12-24	2004-03-18	Lerner E. Itzhak	Controlled release dosage forms
WO2003072055A2 (en)	2002-02-27	2003-09-04	Teva Pharmaceutical Industries, Ltd.	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
DK1567152T3 (da)	2002-11-15	2013-10-07	Teva Pharma	Anvendelse af rasagilin med riluzol til behandling af amyotroph lateral sklerose
WO2004112799A1 (en) *	2003-06-13	2004-12-29	Chrysalis Technologies Incorporated	Methods and apparatus for producing nanoscale particles
US20050026979A1 (en)	2003-07-31	2005-02-03	Maha Ghazzi	Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7735024B2 (en) *	2003-10-29	2010-06-08	Intel Corporation	Methods and apparatus to provide a handheld pointer-based user interface
AU2005269416B2 (en) *	2004-07-26	2011-07-28	Teva Pharmaceutical Industries, Ltd.	Pharmaceutical dosage forms including rasagiline
ZA200704917B (en) *	2004-11-24	2008-11-26	Teva Pharma	Rasagiline orally disintegrating compositions
CA2588293C (en)	2004-11-24	2013-07-02	Teva Pharmaceutical Industries Ltd.	Rasagiline orally disintegrating compositions
JP5738509B2 (ja)	2005-02-23	2015-06-24	テバファーマシューティカルインダストリーズリミティド	内容物均一性が改善されたラサギリン製剤
CN101622225B (zh) *	2005-11-17	2015-04-15	泰华制药工业有限公司	炔丙基氨基茚分离方法
US7572834B1 (en) *	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
JP5701485B2 (ja)	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
WO2007117431A2 (en)	2006-04-03	2007-10-18	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) *	2006-12-14	2011-05-27	Teva Pharma	Tannate salt of rasagiline
CN101557706B (zh)	2006-12-14	2013-08-07	泰华制药工业有限公司	雷沙吉兰碱结晶固体
EP1987816A1 (de)	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
MX2010007601A (es) *	2008-01-11	2010-08-03	Teva Pharma	Formulaciones de rasagilina, su preparacion y uso.

2006
- 2006-02-22 JP JP2007557120A patent/JP5738509B2/ja not_active Expired - Lifetime
- 2006-02-22 EP EP06720975.9A patent/EP1848402B2/en not_active Expired - Lifetime
- 2006-02-22 KR KR1020077021509A patent/KR20070111534A/ko not_active Ceased
- 2006-02-22 AU AU2006216696A patent/AU2006216696B2/en not_active Expired
- 2006-02-22 CA CA2901244A patent/CA2901244A1/en not_active Abandoned
- 2006-02-22 KR KR1020147021536A patent/KR20140103356A/ko not_active Ceased
- 2006-02-22 NZ NZ560660A patent/NZ560660A/en unknown
- 2006-02-22 CA CA2600011A patent/CA2600011C/en not_active Expired - Lifetime
- 2006-02-22 MX MX2007010233A patent/MX2007010233A/es active IP Right Grant
- 2006-02-22 WO PCT/US2006/006252 patent/WO2006091657A1/en not_active Ceased
- 2006-02-22 KR KR1020187006228A patent/KR20180026580A/ko not_active Ceased
- 2006-02-22 BR BRPI0608209-2A patent/BRPI0608209A2/pt not_active Application Discontinuation
- 2006-02-22 ES ES06720975T patent/ES2586412T5/es not_active Expired - Lifetime
- 2006-02-22 RU RU2007135169/15A patent/RU2404746C2/ru active
- 2006-02-22 US US11/359,324 patent/US7815942B2/en active Active
- 2006-02-22 KR KR1020177004882A patent/KR20170023211A/ko not_active Ceased
- 2006-02-22 KR KR1020137025486A patent/KR20130129300A/ko not_active Ceased
2007
- 2007-06-19 IL IL184033A patent/IL184033A0/en unknown
- 2007-08-15 IS IS8669A patent/IS8669A/is unknown
- 2007-09-21 NO NO20074823A patent/NO20074823L/no not_active Application Discontinuation
2013
- 2013-02-12 JP JP2013024784A patent/JP2013139452A/ja active Pending
2016
- 2016-03-28 IL IL244802A patent/IL244802A/en active IP Right Grant

Also Published As

Publication number	Publication date
BRPI0608209A2 (pt)	2010-11-09
HK1103366A1 (zh)	2007-12-21
EP1848402A4 (en)	2012-01-18
IL244802A0 (en)	2016-04-21
KR20070111534A (ko)	2007-11-21
US20060188581A1 (en)	2006-08-24
NO20074823L (no)	2007-11-16
IL244802A (en)	2016-08-31
JP5738509B2 (ja)	2015-06-24
RU2404746C2 (ru)	2010-11-27
KR20170023211A (ko)	2017-03-02
MX2007010233A (es)	2007-11-07
IL184033A0 (en)	2007-10-31
EP1848402A1 (en)	2007-10-31
NZ560660A (en)	2010-11-26
CA2600011C (en)	2015-11-10
KR20140103356A (ko)	2014-08-26
EP1848402B2 (en)	2019-02-20
WO2006091657A1 (en)	2006-08-31
JP2013139452A (ja)	2013-07-18
CA2600011A1 (en)	2006-08-31
KR20130129300A (ko)	2013-11-27
JP2008531572A (ja)	2008-08-14
CA2901244A1 (en)	2006-08-31
RU2007135169A (ru)	2009-03-27
ES2586412T3 (es)	2016-10-14
ES2586412T5 (es)	2019-05-16
US7815942B2 (en)	2010-10-19
EP1848402B1 (en)	2016-05-11
AU2006216696A1 (en)	2006-08-31
AU2006216696B2 (en)	2011-08-18
KR20180026580A (ko)	2018-03-12

Publication	Publication Date	Title
IS8669A (is)	2007-08-15	Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í
TWI348710B (en)	2011-09-11	Conductive compositions and processes for use in the manufacture of semiconductor devices
ATE482618T1 (de)	2010-10-15	Wirkstoffkombinationen
ATE444748T1 (de)	2009-10-15	1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
IL188102A0 (en)	2008-03-20	Self-buffering protein formulations
ATE484194T1 (de)	2010-10-15	Wirkstoffkombinationen
PL2335782T3 (pl)	2021-01-11	Zastosowanie kompozycji zawierającej HFCO-1233zd
PT1883665T (pt)	2017-11-14	Composições polilactídeo e usos das mesmas
ZA200802272B (en)	2009-01-28	Novel dosage formulation
EP1876157A4 (en)	2011-10-26	SEMICONDUCTOR PORCELAIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME
IL184111A0 (en)	2007-10-31	Prostaglandin-containing compositions and methods for enhancing the stability thereof
IL184834A0 (en)	2007-12-03	Compositions and methods for the manufacture thereof
EP1941901A4 (en)	2009-08-05	TOPICALLY APPLIED FORMULATION AND ITS PREPARATION METHOD AND USES
TWI370809B (en)	2012-08-21	Polyacene and semiconductor formulation
ZA200801896B (en)	2009-09-30	Slow-release composition, method for the preparation thereof, and use of the same
ZA200802646B (en)	2009-09-30	Formulation of AICA Riboside
IL185723A0 (en)	2008-01-06	Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
GB0507208D0 (en)	2005-05-18	Anti-inflammatory formulation
GB0526419D0 (en)	2006-02-08	Formulation
ZA200802953B (en)	2009-01-28	Solid vaccine formulation
GB0517673D0 (en)	2005-10-05	Formulation
GB0504924D0 (en)	2005-04-20	Perfume compositions
GB0505702D0 (en)	2005-04-27	Perfume compositions
GB0723011D0 (en)	2008-01-02	Fragrance compositions
ZA200801169B (en)	2010-07-28	Stable solid formulation of sertindole